Ritam Prasad

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Ruben A. Mesa, Alessandro M. Vannucchi, Adam J. Mead et al. · The Lancet Haematology · 2017 · 314 citations · Full text

Medicine, Hematology, Pharmacotherapy +9

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 185 citations

Medicine, Hematology, Pharmacology +9

Verification of the ACL Top 50 Family (350, 550, and 750) for Harmonization of Routine Coagulation Assays in a Large Network of 60 Laboratories

Emmanuel J. Favaloro, Soma Mohammed, Ronny Vong et al. · American Journal of Clinical Pathology · 2021 · 23 citations

Medicine, Hematology, Clinical Biochemistry +16

Acquired haemophilia and haemostatic control with recombinant porcine factor VIII: case series

Sally Campbell, Jane Mason, Ritam Prasad et al. · Internal Medicine Journal · 2020 · 14 citations

Medicine, Hematology, Pharmacotherapy +17

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

Lana A. Castellucci, Vivien Chen, Michael J. Kovacs et al. · New England Journal of Medicine · 2026 · 14 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13